By virtue of their potent induction of haemopoietic malignancies and their well-defined mode of action, the murine leukemia viruses (MLV) are among the most useful tools to study the genetics of these diseases. MLVs act as insertional mutagens which are readily detected in tumour DNA and can be used to identify (tag) host genes that can drive tumour development when aberrantly expressed. Moreover, in combination with transgenic techniques, retroviral gene tagging is a powerful means to demonstrate complementation between genes from different families and to group functionally related genes. 1 While this approach may be limited ultimately by the range of genes susceptible to retroviral mutagenesis, it continues to reveal genes of wide relevance; the set of genes so identified shows increasing overlap with those mutated in human cancers by processes such as chromosomal translocations. In this paper we describe the identification of the Cbfa1 gene, a close relative of the CBFA2 (AML1) oncogene, as a target for insertional mutagenesis in T cell lymphomas initiated by the c-myc oncogene.
The c-myc gene is subject to mutational processes that lead to its unscheduled expression in tumours of various lineages, particularly those of lymphoid origin, and the effects of c-myc deregulation have been widely studied in transgenic mice gene carrying myc constructs linked to tissue-specific transcriptional control elements.
2 Such mice are generally viable but succumb to tumours of clonal origin, demonstrating that Myc overexpression alone is insufficient for the development of the fully malignant phenotype. The rate-limiting steps in Myc transformation are not fully understood but may be explained by the fact that Myc alone does not immortalise haemopoietic cells 3 or that additional changes are required to overcome cell cycle checkpoint controls. 4 Also, overexpression of Myc in serum-starved fibroblasts induces apoptosis rather than proliferation, suggesting that this propensity may have to be countered for efficient tumorigenesis in vivo. 5 Genes that could play a role in completing malignant transformation by Myc have been identified by generation of doubly transgenic mice which succumb more rapidly than either parental type. Myc-collaborating transgenes identified in this way include the apoptotic inhibitor bcl-2, 6 the cellcycle regulator cyclin D1, 7 and inactivated forms of the p53 suppressor gene. 8 Myc-transgenic mice show variable penetrance of the tumour phenotype according to the transgene structure, insertion site and transcriptional control element involved. A particularly marked contrast is seen between the prototypic Emyc strains, with the c-myc transgene linked to the E enhancer, and our CD2-myc lines which carry human c-myc gene linked to the CD2 locus control region (Table 1 ). E-myc mice develop a preleukaemic B cell proliferation and show a high rate of tumour development. 9, 10 In contrast, in CD2-myc strains, a minor proportion develop T cell lymphoma (3-20% according to strain) with no discernible T cell abnormality in the tumour-free animals. 11 Also, while the E-myc transgene is expressed constitutively in B cells, CD2-myc RNA is con- 
Accelerated pre-B No acceleration, but lymphoma (av. 45d) some p53 wt allele loss Some p53 wt allele in tumours loss in tumours fined to malignant cells. Although the rate-limiting step in CD2-myc lymphoma may be transcriptional activation of the transgene, a more interesting possibility is that the developmental activation of this transgene causes apoptosis rather than proliferation and is therefore counterselected during fetal development, with acquired resistance as the rate-limiter for tumour outgrowth. With this hypothesis in mind we tested the effect of crossing CD2-myc with p53null mice. However, this experiment failed to resolve the issue as no differences were observed in apoptotic rates of p53null tumours, despite strong oncogenic synergy between CD2-myc and p53, (Ref. 8, K Blyth, unpublished). Similar observations have been made in E-myc × p53null mice, where it appears that the proliferative rate, but not the apoptotic rate, is affected by p53 status. 12 In contrast to crossing with p53−/−, where a large difference in oncogenic potency is retained between E-myc and CD2-myc, MLV infection leads to a quite similar pattern of tumour penetrance and onset in both strains (Table 1) , with clonal MLV insertion a feature in each case. It is conceivable that the genes targeted by viral insertion provide the collaborating functions required and that it is these that nullify the differences in oncogenic efficiency of the two transgenes. In Emyc mice, retroviral gene tagging has identified two complementation groups of Myc-collaborating genes, the first represented by the Pim protein kinase family and the second by at least two structurally unrelated transcription factors (gfi-1, bmi-1) which appear to be the critical targets of two series of linked insertion clusters. Although these myc-collaborating genes are not strictly lineage-restricted and are frequently activated in MLV-induced T cell as well as B cell tumours 1 we found that very few virus-accelerated CD2-myc tumours involved these loci. Instead, analysis of the sites of MLV inser-
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Figure 1
Map of the til-1 insertion cluster and the Cbfa1 gene. Viral insertions (arrowheads) are upstream and in the opposite orientiation to Cbfa1. The empty arrowhead indicates the index tumour from which the rearranged locus was cloned. The til-1E probe and RT-PCR primers from this domain detect transcripts in tumours with insertions at til-1 and in osteoblast or osteosarcoma cell lines. Previously identified transcripts from the gene (in 3T3, EL4, BW5147 cells) appear to derive from another promoter element far downstream from the til-1 site. Alternative splicing and exon skipping gives rise to numerous isoforms (see Figure 2) . tion in these tumours showed that around one third had insertions at a novel locus on chromosome 17, far from any known proviral insertion target, which we designated til-1. 13 Further analysis of murine DNA 3Ј to the til-1 insertion cluster yielded a single copy sequence probe with which we detected a tumour-specific transcription unit; an abundant 5.5 kb mRNA was seen in lymphoma cell lines with insertions at the locus but not in unaffected lines or in a wide range of normal mouse tissues (Figure 1 ). Cloning of cDNA from a representative tumour cell line (47i) showed that these transcripts encode isoforms of CBF␣1, a transcription factor belonging to a three-member mammalian family related to the Drosophila segmentation gene product, Runt. The cDNAs from 47i cells differ from the previously described Cbfa1 gene (formerly PEBP2␣A) transcripts at the 5Ј end, and encode an alternative, slightly longer, N-terminal domain. In addition, minor CBF␣1 isoforms are expressed which differ by internal exon skipping or by alternative 3Ј splicing to generate a divergent C-terminal protein domain (Y). Analysis of CBF-specific DNA binding activity in nuclear extracts from 47i lymphoma cells shows that most of this activity corresponds to the abundant G isoforms of CBF␣1 14 ( Figure 2 ).
Figure 2
Comparison of CBF␣ isoforms in normal and neoplastic tissue. Known isoforms of the mouse CBF␣1 and CBF␣2 are shown, alongside those of the human CBFA2 oncogene which is affected by various translocations in myeloid leukaemias (C-terminal fusions with ETO, EVI1, etc) or childhood B-ALL (N-terminal fusion with the Ets-related ETV6). The Runt homology domain (RHD), which mediates DNA binding, is retained in all fusion products and isoforms. However, the putative transactivation domain (TA) is lost from some splice variants and Cterminal fusions, and is replaced in minor til-1 isoforms by an alternative PEST-rich domain of unknown function (Y). Block shading at the Nterminus shows the related sequences of tissue-specific forms of CBF␣2 (AML1c) and CBF␣1 (til-1/bone transcripts). Previous literature designations of these isoforms are shown for convenience.
Cbfa1 transcription was previously found to be restricted to a narrow range of cells including normal thymus, selected T lymphoma cell lines (EL4, BW5147) and Ras-transformed 3T3 cells. 15 However, using probes derived from the variant til-1 5Ј end we found that the gene was also expressed in osteosarcoma cell lines and in normal cultured osteoblasts. 16 This pattern of bone-specific expression is intriguing in view of the recent demonstration that mice with a homozygous deletion of Cbfa1 fail to develop mature bone. Moreover, heterozygotes display a phenotype similar to the human skeletal malformation syndrome, cleidocranial dysplasia (CCD), which maps to mutations in the homologous human gene, CBFA1. [17] [18] [19] It appears that CBF␣1 is required for the expression of key genes in the osteoblast differentiation programme. 20 The role of CBF␣1 in T cell development is as yet unclear, as no obvious T cell abnormality was noted in the knockout mice. Other CBF family members are co-expressed in T cells, 15 suggesting that redundancy may apply in this lineage.
Surprisingly, we found that proviral insertions at til-1 in CD2-myc lymphomas target exclusively the bone-specific upstream promoter of Cbfa1. RT-PCR analysis of a panel of CD2-myc lymphomas revealed very good correspondence between insertions at til-1 detected by Southern blots and transcripts containing the upstream exons. Our results show that viral insertion is exclusively in the opposite orientation to the transcription unit (the enhancer insertion mode) and that the result is activation of transcription from the normally bonespecific promoter (Figure 1) .
The functional consequences of Cbfa1 activation have yet to be determined. The close relative CBFA2 (AML1) has emerged as the most frequently affected gene in human leukaemias (AML, CML, pro-B ALL), undergoing various chromosomal translations which generate novel fusion proteins (eg ETV6-CBFA2, CBFA2-ETO). These fusion products appear to interfere with the ability of the normal CBFA2 product and its heterodimeric binding partner (CBF␤) to trans-activate key genes involved in myeloid differentiation, by a dominant negative mechanism. [21] [22] [23] [24] Our observations suggest that overexpression of the full-length Cbfa1 gene can also have oncogenic consequences, at least in the presence of Myc overexpression in the T cell lineage. While an interference model can be envisaged if these homologues and isoforms interact, a positive transforming role must also be considered. Binding sites for the CBF proteins are found in a variety of viral and cellular promoters including growth factors and T cell receptor genes, presenting a number of potential explanations for collaboration with Myc. It is possible that Cbfa1 generates a potent T cell survival signal which interferes strongly with Myc-induced apoptosis. However, we cannot discount the possibilities that Cbfa1 is an activator of the CD2-myc transgene or even a feedback regulator of the viral LTR enhancer. Experiments to test the effects of over-expressing Cbfa1 alone or in other transgenic backgrounds are now under way.
A final point of note is that the bone-specific and virusactivated (til-1) isoforms of CBF␣1 differ at the N-terminus from the previously known isoforms. Similarly, the CBFA2 (AML1) gene has an alternative far upstream promoter and Nterminal variants with sequence homology to those of til-1/CBF␣1 (see Figure 2) . The CBFA2 (AML1c) variant promoter is expressed in a tissue-specific fashion, principally in thymus and spleen. 25 It is conceivable that the N-terminal variants differ in function and that their ectopic expression has oncogenic consequences.
Our results bring together Myc and CBF, two of the most frequently implicated gene families in human leukaemia, as potential collaborators in the genesis of T cell lymphoma. Understanding the mechanism by which they cooperate, and the basis of the selection of CBF over other potential Myc collaborators in the CD2-myc model, may help to unravel the complex selective process that underlies lymphoid tumour development.
